GE HealthCare has announced positive results from a Phase I study of its manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Data from the first-in-human trial – presented at ...

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

A twist on magnetic resonance imaging that does not require gadolinium contrast appears to be as effective as standard imaging at detecting prostate cancers, according to a new study in JAMA. Experts ...

Leesburg, VA, September 14, 2022—According to ARRS’ American Journal of Roentgenology (AJR), the contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging ...

Magnetic Resonance Imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated for its non-ionizing and non-invasive nature. With nearly 40% of MRI procedures requiring contrast ...

MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...

Contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging modalities to better identify areas of prior biopsy during breast MRI interpretation, according to a ...